featured
Ibrutinib–Rituximab Followed by R-HCVAD as Frontline Treatment for Young Patients With Mantle Cell Lymphoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
The Lancet Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Ibrutinib-rituximab followed by R-HCVAD as frontline treatment for young patients (≤65 years) with mantle cell lymphoma (WINDOW-1): a single-arm, phase 2 trial
Lancet Oncol 2022 Jan 21;[EPub Ahead of Print], ML Wang, P Jain, S Zhao, HJ Lee, L Nastoupil, L Fayad, CY Ok, R Kanagal-Shamanna, HA Hill, Y Yao, FB Hagemeister, JR Westin, N Fowler, F Samaniego, R Steiner, R Nair, SP Iyer, L Navsaria, M Badillo, , L Feng, H Xuelin, GM Nogueras Gonzalez, G Xu, N Wagner-Bartak, S Thirumurthi, D Santos, G Tang, P Lin, SA Wang, J Jorgensen, CC Yin, S Li, KP Patel, F Vega, LJ Medeiros, CR Flowers, L WangFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.